Tejara Capital Ltd Invests $410,000 in Keros Therapeutics, Inc. $KROS

Key Points

• Tejara Capital Ltd acquired 40,245 shares of Keros Therapeutics, Inc. for approximately $410,000, which now represents about 0.10% of the company's stock.
• Keros Therapeutics posted a quarterly earnings report showing an EPS of ($0.76), surpassing expectations, but its revenue was significantly below estimates at $0.02 million.
• Wall Street analysts have mixed ratings on Keros Therapeutics, with an average price target of $30.00 and seven analysts rating the stock as a "buy."

Tejara Capital Ltd bought a new stake in Keros Therapeutics, Inc. (NASDAQ:KROS - Free Report) during the 1st quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund bought 40,245 shares of the company's stock, valued at approximately $410,000. Tejara Capital Ltd owned approximately 0.10% of Keros Therapeutics as of its most recent filing with the Securities and Exchange Commission.

Several other institutional investors have also recently bought and sold shares of KROS. Entropy Technologies LP bought a new stake in shares of Keros Therapeutics during the 1st quarter worth approximately $121,000. Invesco Ltd. raised its stake in shares of Keros Therapeutics by 163.7% during the 1st quarter. Invesco Ltd. now owns 33,266 shares of the company's stock worth $339,000 after purchasing an additional 20,650 shares in the last quarter. Covestor Ltd raised its stake in shares of Keros Therapeutics by 1,230.8% during the 1st quarter. Covestor Ltd now owns 17,061 shares of the company's stock worth $174,000 after purchasing an additional 15,779 shares in the last quarter. Connor Clark & Lunn Investment Management Ltd. raised its stake in shares of Keros Therapeutics by 339.5% during the 1st quarter. Connor Clark & Lunn Investment Management Ltd. now owns 128,103 shares of the company's stock worth $1,305,000 after purchasing an additional 98,957 shares in the last quarter. Finally, Vanguard Group Inc. raised its stake in shares of Keros Therapeutics by 31.1% during the 1st quarter. Vanguard Group Inc. now owns 2,566,321 shares of the company's stock worth $26,151,000 after purchasing an additional 609,212 shares in the last quarter. Institutional investors own 71.56% of the company's stock.

Keros Therapeutics Stock Down 0.2%

Shares of KROS traded down $0.03 during trading hours on Tuesday, hitting $14.49. 512,215 shares of the company were exchanged, compared to its average volume of 980,057. The company has a market cap of $588.58 million, a price-to-earnings ratio of 46.74, a P/E/G ratio of 1.78 and a beta of 1.33. Keros Therapeutics, Inc. has a fifty-two week low of $9.12 and a fifty-two week high of $72.37. The firm's fifty day moving average is $13.94 and its 200 day moving average is $12.91.

Keros Therapeutics (NASDAQ:KROS - Get Free Report) last released its quarterly earnings data on Wednesday, August 6th. The company reported ($0.76) earnings per share for the quarter, beating the consensus estimate of ($1.14) by $0.38. The business had revenue of $0.02 million for the quarter, compared to analyst estimates of $3.83 million. Keros Therapeutics had a return on equity of 2.96% and a net margin of 8.06%.Keros Therapeutics's revenue was up 49002.7% compared to the same quarter last year. During the same period last year, the firm posted ($1.25) earnings per share. Analysts anticipate that Keros Therapeutics, Inc. will post -4.74 EPS for the current year.

Wall Street Analyst Weigh In

KROS has been the topic of a number of recent analyst reports. Bank of America lowered Keros Therapeutics from a "buy" rating to a "neutral" rating and decreased their target price for the stock from $32.00 to $18.00 in a report on Tuesday, June 10th. Scotiabank decreased their target price on Keros Therapeutics from $41.00 to $26.00 and set a "sector outperform" rating on the stock in a report on Monday, May 12th. Wedbush reissued a "neutral" rating and set a $15.00 target price on shares of Keros Therapeutics in a report on Friday, May 30th. Finally, HC Wainwright decreased their target price on Keros Therapeutics from $25.00 to $20.00 and set a "buy" rating on the stock in a report on Friday, August 8th. Seven analysts have rated the stock with a Buy rating and seven have assigned a Hold rating to the company's stock. Based on data from MarketBeat.com, the stock presently has a consensus rating of "Moderate Buy" and a consensus price target of $30.00.

Keros Therapeutics Profile

Keros Therapeutics, Inc, a clinical-stage biopharmaceutical company, develops and commercializes novel therapeutics for patients with disorders that are linked to dysfunctional signaling of the transforming growth factor-beta family of proteins in the United States. The company's lead product candidate is KER-050, which is being developed for the treatment of low blood cell counts, or cytopenias, including anemia and thrombocytopenia in patients with myelodysplastic syndromes, as well as in patients with myelofibrosis.